Please insert the substitute Sequence Listing information (copy enclosed) after the last page of the Substitute Specification (page 15) to replace the original Sequence Listing contained in the Substitute Specification.

In the Drawings:

In accordance with 37 C.F.R. § 1.121(d), proposed changes to Figures 1 and 2 are marked in red for approval by the Examiner on copies of the figures submitted herewith.

In the Claims:

Please cancel claims 1/17 without prejudice or disclaimer of the subject matter contained therein. Please add new claims 18-50 listed below. This list represents all of the claims that will be presently pending.

Pending Claims


New) A particle comprising:

- (a) a protein envelope with a fusion protein, the fusion protein comprising a virus protein, a cell permeability-mediating peptide, and a heterologous cell-specific binding site; and
- (b) nucleic acid sequences present in the protein envelope, each of the nucleic acid sequences comprising a sequence encoding a virus-specific packaging signal and a sequence encoding a structural gene.
- 19. (New) The particle of claim 18, wherein the virus protein is derived from the group consisting of adenovirus, adeno-associated virus, vaccinia virus, baculovirus and hepadnavirus.
- 20. (New) The particle of claim 19, wherein the hepadnavirus is a hepatitis B virus.

The particle of claim 18, wherein the virus protein is a surface protein. wherein the surface protein is an LHBs. The particle of claim 22 The particle of claim 18, wherein the virus protein is a core protein. The particle of claim 23, wherein the core protein is an HBcAg. The particle of claim 18, wherein the cell permeability-mediating 1425. (New) peptide comprises the amino acid sequence set forth in SEQ ID NO:20. The particle of claim 1/8, wherein the heterologous cell-specific 6. (New) binding site is RGD. The particle of claim 18, wherein the fusion protein comprises an 7. (New) amino acid sequence selected from the group consisting of SEQ ID NO:1 and SEQ ID NO:2. The particle of claim 18, wherein the fusion protein comprises the 8. (New) amino acid sequence set forth in SEQ ID NO:1. The particle of claim 18, wherein the fusion protein has the amino 9. (New) acid sequence set forth in SEQ ID NO:1. The particle of claim 18, wherein the fusion protein comprises the). (New) amino acid sequence set forth in SEQ ID NO:2. The particle of claim 18, wherein the fusion protein has the amino (New) acid sequence set forth in SEQ ID NO:2. A method for the preparation of the particle according to claim 18, (New)

wherein the fusion protein contains an LHBs and a heterologous cell-specific

binding site, the method comprising:



isolating and purifying the particle. (b)

- A method for the preparation of the particle according to claim 18, ¹⁾33. (New) wherein the fusion protein comprises an HBcAg, a cell permeabilitymediating peptide and a heterologous cell-specific binding site, the method comprising:
 - cotransfecting cells containing an HBV polymerase with a first (a) expression vector coding for a fusion protein, the fusion protein comprising an HBcAg, a cell permeability-mediating peptide and a heterologous cell-specific binding site, and with a second expression vector comprising a virus-specific packaging signal and a structural gene, and

isolating and purifying the particle. (b)

A fusion protein comprising a virus protein, a cell permeabilitymediating peptide and a heterologous cell-specific binding site.

The fusion protein of claim 34, comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1 and SEQ ID NO:2.

The fusion protein of claim 34, comprising the amino acid sequence (New) set forth in SEQ ID NO:1.

The fusion protein of claim 34, comprising the amino acid sequence '. (New) set forth in SEQ ID NO:2

- 38. (New) The fusion protein of claim 35, wherein the amino acid sequence differs from that set forth in SEQ ID NO:1 or SEQ ID NO:2 by one amino acid.
- 39. (New) The fusion protein of claim 38, wherein the amino acid sequence differs from that set forth in SEQ ID NO:1 or SEQ ID NO:2 by up to 10%.
- 40. (New) The fusion protein of claim 35, wherein the amino acid sequence differs from that set forth in SEQ ID NO:1 or SEQ ID NO:2 by up to 20%.
 - $\frac{1}{4}$. (New) A DNA encoding the fusion protein of claim $\frac{34}{34}$
 - (New) A DNA encoding the fusion protein of claim 38, the DNA comprising a nucleotide sequence selected from the group consisting of SEQ ID NO:3 and SEQ ID NO:4.
 - (New) A DNA encoding the fusion protein of claim 35, the DNA comprising the nucleotide sequence set forth in SEQ ID NO:3.
 - (New) A DNA encoding the fusion protein of claim 35, the DNA comprising the nucleotide sequence set forth in SEQ ID NO:4.
- (New) The DNA of claim 42, wherein the nucleotide sequence differs from that set forth in SEQ ID NO:3 or SEQ ID NO:4 by one base pair.
- (New) The DNA of claim 42, wherein the nucleotide sequence differs from that set forth in SEQ ID NO:3 or SEQ ID NO:4 by up to 10%.
- (New) The DNA of claim 42, wherein the nucleotide sequence differs from that set forth in SEQ ID NO:3 or SEQ ID NO:4 by up to 20%.
- 48. (New) A DNA encoding the fusion protein of claim 35, wherein the DNA has the nucleotide sequence set forth in SEQ ID NO:3.
- 49. (New) A DNA encoding the fusion protein of claim 35, wherein the DNA has the nucleotide sequence set forth in SEQ ID NO:4.